ArticleFrontiers in microbiology2026
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: The antimicrobial and anti-virulence activity of the iminosugar Results and discussion: L-NPDNJ exhibited weak bactericidal activity but showed additive effects when used in combination with amikacin and tobramycin, reducing their minimum inhibitory concentrations by two- to threefold. At sub-inhibitory concentrations, L-NPDNJ was found to significantly modulate the expression of genes involved in antibiotic resistance, biofilm regulation, and virulence, including those encoding efflux pumps, global regulators, and extracellular proteases. These transcriptional changes were found to be associated with significant phenotypic effects. At sub-inhibitory concentrations, L-NPDNJ reduced cell surface hydrophobicity by up to 90%, impaired adhesion to abiotic surfaces and to human lung epithelial cells by over 90%, and disrupted preformed biofilms, decreasing biofilm biomass and metabolic activity by approximately 70%. In addition, L-NPDNJ has been shown to enhance macrophage phagocytosis and reduce intracellular bacterial survival, while improving epithelial cell viability. Notably, pretreatment of Conclusion: Collectively, these findings demonstrate that L-NPDNJ exerts a broad anti-virulence effect against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.